Management report

1
Management report

• Elda.Rossi_at_cineca.it

2
agenda

• Where we are now and whats next
• Outcome of the first review meeting
• The new Officer
• Status of deliverables and reports
• Miscellanea

3
The project organisation

• Milestones
• MS1 WP1 delivers first draft concepts
• MS2 WP4 delivers the design (draft) of the
  simulator
• MS3 WP5-6 deliver the first prototype of the
  simulator
• MS4 WP4 delivers the final design of the
  simulator
• MS5 WP5-6 deliver final simulator prototype
• MS6 End of Project
• WP1 delivers final document on standardized
  concepts
• WP7-8 deliver final assessment report on the
  simulator

4
MS 1

• Integration of standardized concepts and
  information on molecular, cellular, and organ
  level for the description of immune system
  processes and function a preliminary internal
  version at month 6 and a final public release at
  month 36 (end of project)
• Design of the simulator and associated
  information flow a first draft at project-month
  10
• Implementation of the simulator on the Grid with
  the required data repository a first draft at
  project-month 18 and a final prototype at month
  32 (Milestone 5)
• final design at month 24
• Assessment of the simulator for preclinical and
  clinical applications preliminary results during
  the project, final outcome at month 36 (end of
  project)

MS 2
MS 3
MS 4
5
Future plans

• Milestones
• MS3 WP5-6 deliver the first prototype of the
  simulator
• MS4 WP4 delivers the final design of the
  simulator
• MS5 WP5-6 deliver final simulator prototype
• MS6 End of Project
• WP1 delivers final document on standardized
  concepts
• WP7-8 deliver final assessment report on the
  simulator

6
Outcome of the first review meeting
7
(No Transcript)
8
??
9
Batterial infection innate immunological
responseunderrepresented
10
Molecular System integration Natural
immuneSystem
Focus on specificsimulation types Clear
exploitation plan
11
Too much time spent in writingdeliverables
12
(No Transcript)
13
More concretecooperation withother projects
14
Exploitation disseminationplan to be done
15
Human ??
Ethical aspects to be clarified
16
(No Transcript)
17
More focus
Clinical validation
Exploitation Plan
Dissemination Plan
18
Future plans
19
(No Transcript)
20
The new officer
21
Status of deliverables and reports

• D1.2 Scientific chart rules and ontologies report
  (CNRS)
• D2.2 Models prototypes for molecular
  interactions (Second draft) (DTU)
• D3.3 Model components, strategies and prototypes
  second draft (CNR)
• D5.1 Common repository of data required by the
  simulator (Birkbeck)
• D6.2 Specification of the grid implementation
  (first draft) (CINECA)
• D6.3 First prototype of the VHIS simulator
  (CINECA)
• D7.1 Report on the experiment planning for
  assessing the simulator (UniBO)
• D8.1 Report on the experiment planning for
  assessing the simulator (UQ)
• D9.3 ImmunoGrid tutorial for conferences/workshop
  (UniCT)
• 18 months Activity report (all partners)
• 18 months Management report (all partners)

22
Miscellanea
23
Dear Elda,   It was a pleasure speaking with you.
Following our conversation I have attached
information concerning The Parliament Magazine
together with our proposal for ImmunoGrid
project.   If you are not familiar with The
Parliament Magazine please visit our website on
http//www.theparliament.com/EN/Magazine/  where
you can download some of the recent
editions.   We are now working on the 17th
September edition which will incorporate the
Research Review supplement. One of the key areas
of focus in this issue will be ICT in Health.
Please refer to the attached document for more
information about the supplement. The supplement
will benefit from the same distribution as the
main magazine. In addition to this we are sending
out extra 1,000 copies to heads of research. We
have also teamed up with two events to distribute
the Research Review to all attendees of the
Health Forum Gastein in Austria as well as the
17th annual eChallenges conference in The Hague,
Netherlands.   We are working closely with Janez
Potocnik, Commissioner for Science and Research
who will also contribute editorially. This is a
great opportunity to communicate your message and
write about ImmunoGrid project as all MEPs and
Commissioners who deal with Health, ICTs,
Research and funding will be very keen to read
this edition. The Parliament Magazine provides a
small number of dissemination opportunities for
relevant projects. As your project fits in quite
well with our editorial we would like to invite
you to participate by taking one of the available
spaces. You can use your space to showcase your
work and write about the project, disseminate
results, announce events or communicate any other
message to MEPs and Commissioners. I have a Full
Page and a Half Page available at the moment. The
regular rate card cost for these positions is
6,700 net and 3,700 net respectively. We do
have special rates for projects which include 25
discount. This will bring the total cost of your
participation down to 5,025 net for a Full Page
or 2,775 net for a Half Page. Copy date for
this edition is 10th September. A Full Page will
give you up to 600 words of text together with a
couple of logos/images. Alternatively, you can
have up to 300 words and one or two images or
logos on a Half Page. We are happy to design your
artwork for you at no extra cost and we will send
the materials back to you for approval prior to
the publication. Elda, please do not hesitate to
contact me if you or your colleagues have any
queries or need more information. Otherwise, I
will get back to you mid next week as agreed.
  I wish you a nice weekend. Kind
Regards,     Anka Prpa 
24
Only one simulator!
25
The project Web-site

• At present a web-site is available based on PLONE
  Content Management
• The focus is on the content, not the container
• Everyone can manage the site (without knowledge
  of html, php, ...)
• Possible to define roles

26
The new call

• Patient-specific computer models for personalised
  and predictive healthcare and ICT based tools for
  modelling and simulation of human physiology and
  disease-related processes.
• a) Patient-specific computational modelling and
  simulation of organs or systems targeting
  specific clinical needs such as prediction of
  diseases, early diagnosis, disease
  quantification, surgery planning, treatment and
  training. The computational models should go
  beyond the state of the art of available models
  and be multilevel when appropriate. Projects will
  address one or more of the clinical application
  areas defined in the paragraph below Clinical
  applications and demonstrations.
• b) Data integration and new knowledge extraction
  Innovative software tools for data mining,
  representation, formalisation and image
  processing able to integrate heterogeneous
  multimedia information from distributed
  databases. These tools will be developed
  specifically for (1) Coupling scientific research
  data with clinical and large empirical databases
  with focus on the association of genotype-related
  data and phenotype-related data with specific
  computational models of diseases and treatments
• (2) Automated image processing and analysis for
  the extraction of bio-medical parameters/markers
  used to assess the presence or evolution of a
  disease, focusing on specific organs and/or
  disease and demonstrating quantitative benefits
  in diagnosis and prognosis. Projects will address
  one of the clinical application areas defined in
  the paragraph below Clinical applications and
  demonstrations.
• c) Clinical applications and demonstration of
  tangible benefits of patient-specific
  computational models All projects addressing the
  two technical bullets above will fall into one of
  the following application areas (1) Intelligent
  medical simulation environments for surgery
  training, planning and interventions (2)
  Prediction of disease or early diagnosis by
  integrating patient specific knowledge and
  predispositions obtained in biomedical imaging
  (3) Advanced environment for simulation and
  assessment of the efficacy and safety of specific
  drugs. All models will be fully verified and
  validated, so that they can be deployed as part
  of an ICT infrastructure that provides integral
  access to clinical users. The use of open
  environments and open-source software is expected
  to allow for future extensions of models.
• d) Networking action on integrating European
  research in the field of multilevel modelling and
  simulation of human anatomy and physiology.
  Sustainable integration will be achieved through
  a rather limited partnership with demonstrated
  scientific excellence. Jointly executed research
  will focus on methodological issues and
  mechanisms that favour sharing knowledge,
  multidisciplinary training programmes and
  reusable software tools.
• e) Coordination and support actions on (1)
  Enhancing security and privacy in VPH, in
  particular for patient data processed over
  distributed networks. The proposed solutions will
  address the implications of the use of genetic
  data, e.g. genetic predispositions, and identify
  the required technology developments and
  implementation challenges. (2)
• Specific International Cooperation Action on
  healthcare information systems based on Grid
  capabilities. Insight into research activities
  undertaken in the target countries of Latin
  America, Western Balkans, Mediterranean
  countries, aiming at optimizing the use of
  bio-medical data and computing resources. New
  opportunities for collaboration will be explored
  and a set of future activities identified.
• Expected impact
• New environments for predictive, individualised,
  evidence based, more effective and safer
  healthcare. Reduced medical errors and improved
  patient safety through simulation of adverse drug
  effects on patient models. Accelerated
  development of safer drugs and medical devices
  through in-silico environments.